Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry

- CD presents clinically with a wide range of symptom severity and comorbidities.
- AbobotulinumtoxinA efficacy in “real life” was consistent with controlled trials.
- Most common adverse events were dysphagia, muscular weakness, neck pain, and rhinorrhea.
- Safety profile was consistent with the pivotal placebo-controlled trials.

BackgroundThe ANCHOR-CD prospective observational registry study evaluated the effectiveness of abobotulinumtoxinA in adult idiopathic cervical dystonia (CD) in clinical practice.MethodsAdults with CD were eligible. Treating physicians determined abobotulinumtoxinA dose and treatment interval. The primary endpoint was patient response rate (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] score reduction ≥ 25% and Patient Global Impression of Change [PGIC] score of + 2 or + 3 at Week 4 of Cycle 1).Results350 patients enrolled (75% women; mean age 59 ± 13.6 years; 27.4% botulinum neurotoxin-naive) and 347 received at least 1 treatment. The median abobotulinumtoxinA dose for Cycle 1 was 500 Units. At Week 4, the responder rate was 30.6% (n = 304) and the TWSTRS total score decreased 27.4% from baseline. PGIC of at least “Much improved” was documented in 43.6% of patients and maintained in Cycles 2 through 4 (43.3%, 48.9%, and 52.8%, respectively). A total of 39 adverse events (31 study drug-related) were reported in 17 patients (5%); the most common were dysphagia (n = 6), muscle weakness (n = 4), and neck pain (n = 3).ConclusionThis study confirmed the beneficial effect of abobotulinumtoxinA on CD in routine clinical practice as measured by improvements in TWSTRS and PGIC. No new safety concerns were identified.